- Home
- CRMD vs BBOT Comparison
CRMD vs BBOT Comparison
Compare CRMD & BBOT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CRMD | BBOT |
|---|---|---|
| Founded | 2006 | 2016 |
| Country | United States | United States |
| Employees | N/A | 106 |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 626.0M | 705.7M |
| IPO Year | 2009 | N/A |
Fundamental Metrics
Financial Performance| Metric | CRMD | BBOT |
|---|---|---|
| Price | $8.46 | $8.64 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 6 | 7 |
| Target Price | $14.83 | ★ $24.00 |
| AVG Volume (30 Days) | ★ 1.3M | 356.1K |
| Earning Date | 05-11-2026 | 05-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 780.00 | N/A |
| EPS | ★ 0.43 | N/A |
| Revenue | ★ $311,709,000.00 | N/A |
| Revenue This Year | $0.30 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $19.59 | ★ N/A |
| Revenue Growth | ★ 617.03 | N/A |
| 52 Week Low | $6.13 | $7.60 |
| 52 Week High | $17.43 | $14.87 |
Technical Indicators
Market Signals| Indicator | CRMD | BBOT |
|---|---|---|
| Relative Strength Index (RSI) | 63.26 | 51.85 |
| Support Level | $6.14 | $8.08 |
| Resistance Level | $8.53 | $9.50 |
| Average True Range (ATR) | 0.38 | 0.57 |
| MACD | 0.05 | 0.07 |
| Stochastic Oscillator | 68.54 | 68.17 |
Price Performance
Historical ComparisonAbout CRMD CorMedix Inc.
Cormedix Inc is a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions. The Company's focus is on the commercialization of its product, DefenCath, in the United States and other key markets. The group currently operates in a single segment, Drug Product, located in a single geographic location, the United States.
About BBOT BridgeBio Oncology Therapeutics Inc.
BridgeBio Oncology Therapeutics Inc, is a clinical-stage biotechnology company that aims to transform the lives of patients with cancers driven by RAS and PI3Ka, the two frequently mutated oncogenes. The Company operates in one operating and reportable segment within the United States, developing oncology therapies through various related development projects.